End-stage renal disease in developing countries  by Kher, Vijay
Kidney International, Vol. 62 (2002), pp. 350–362
NEPHROLOGY FORUM
End-stage renal disease in developing countries
Principal discussant: Vijay Kher
Department of Nephrology, Indraprastha Apollo Hospitals, New Delhi, India
paradoxus of 20 mm Hg, and cardiac sounds were muffled.
Chest examination disclosed basal crepitations. Examination
of the abdomen revealed hepatomegaly and ascites. Central
nervous system examination revealed that the patient was in
grade III coma with no localizing neurologic signs. He was
clinically diagnosed as having advanced renal failure with peri-
cardial effusion. Investigations revealed 3 urinary albumin,
no sugar, and 4 to 5 granular and broad casts/high-power field;
hemoglobin, 4.8 g/d; hematocrit, 14%; white blood cell count,
8700/mm3; and platelet count, 260,000/mm3. A peripheral smear
revealed marked anisocytosis and hypochromia. Blood sugar
was 80 mg/dL; blood urea, 380 mg/dL; serum creatinine, 22
mg/dL; uric acid, 14 mg/dL; sodium, 126 mmol/L; potassium,
5.4 mmol/L; chloride, 94 mmol/L; total protein, 5.0 g/dL; and
serum albumin, 2.2 g/dL. The serum calcium was 8.2 mg/dL;
phosphorus, 10 mg/dL; and alkaline phosphatase, 230 IU/L.CASE PRESENTATIONS
Arterial blood revealed pH 7.2; PCO2, 28; HCO3 , 12 mEq/L.Patient 1. A 24-year-old man, an unskilled worker in a small A chest radiograph disclosed severe cardiomegaly with conges-
shop, was admitted with a two-day history of shortness of tion in the lung parenchyma. Echocardiography revealed a
breath and altered sensorium. He had been admitted to a large anterior and posterior pericardial effusion. An emergency
government hospital twice previously. The first time, 4 years
pericardiocentesis drained 600 mL of hemorrhagic fluid. Heearlier, he had edema and high blood pressure. The 24-hour
also received 3 units of packed cells and hemodialysis throughprotein excretion was 3.2 g; creatinine clearance, 26 mL/min;
a femoral catheter. He developed fever and breathlessness onserum creatinine, 3.8 mg/dL; and blood urea, 100 mg/dL; ultra-
day 4 of his admission, had to be ventilated for acute respiratorysound examination disclosed bilaterally small kidneys. A renal
failure secondary to bilateral staphylococcal pneumonia, andbiopsy was not performed. He was given amlodipine, 10 mg
died on day 7.twice daily; prazosin, 5 mg twice daily; and calcium carbonate,
Patient 2. A 68-year-old businessman with a 20-year history500 mg three times daily with meals. He was advised to monitor
of diabetes mellitus initially controlled on glibenclamide andhis blood pressure and be monitored regularly. He did not
metformin was now controlled on injectable human insulin, 40comply with the advice.
U/day. He also had hypertension of 10 years duration that wasThe second admission occurred six weeks ago, when he pre-
controlled currently with clonidine, 0.6 mg/day, and amlodi-sented with advanced azotemia. He underwent two hemodialy-
pine, 10 mg/day. He had had pedal edema one year previously.sis sessions through a double-lumen femoral catheter and was
The 24-hour urinary protein was 2.4 g; creatinine clearancedischarged and advised to continue hemodialysis as an outpa-
was 24 mL/min. His vision had been affected and an ophthal-tient and look for a kidney donor in the family. He defaulted
mologist had treated both eyes with laser. He was admitteduntil the current admission.
now with loss of appetite, occasional vomiting, and weakness.On examination he was malnourished with obtunded senso-
He denied chest pain, claudication, or urinary complaints.rium. The pulse was 116 beats/min and regular; blood pressure,
Physical examination revealed a pleasant elderly gentleman.90/70 mm Hg; and respiratory rate, 30 breaths/min. He was
His blood pressure was 150/80 mm Hg; pulse, 80 beats/min andseverely anemic with uremic fetor, anasarca, and a raised jugu-
regular. All peripheral pulses were palpable, he had no carotidlar venous pressure. Cardiomegaly was present, as was pulsus
or renal bruit, respiratory rate was 18 breaths/min, and pedal
and leg edema were present. Temperature was 98F; weight,
84 kg; height, 58″. He was anemic, and the jugular venous
The Nephrology Forum is funded in part by grants from Amgen,
pressure was not raised. He had cardiomegaly and sensory–Incorporated; Merck & Co., Incorporated; Dialysis Clinic, Incorpo-
motor peripheral neuropathy.rated; and Bristol-Myers Squibb Co.
Laboratory investigation revealed a 24-hour urinary protein of
Key words: chronic renal failure, hemodialysis, continuous ambulatory 1.8 g; creatinine clearance, 7 mL/min; urine culture, sterile; hemo-
peritoneal dialysis. globin, 9.6 g/dL; white blood cell count, 9400 mm3, unremarkable
differential counts, erythrocyte sedimentation rate, 34 mm at 2002 by the International Society of Nephrology
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Table 2. Comparative statistics of developed andTable 1. Economic classificationa
developing countriesa
Total Annual
No. of population per capita Parameter Developed Developing India
Group countries billion GNP US$
Population, billions 0.93 4.90 0.997
Urban, % 74 31 28High 50 0.93 9265
Upper middle 38 0.57 2996–9265 Life expectancy, years 78 62 63
Birth rateb 14 32 27Low middle 55 2.28 755–2995
Low 64 2.05 755 Infant mortality ratec 13 77 70
Annual increased, % 0.5 1.9 1.7a From Ref. 2
Per capita GNP, US$ 25,700 1,230 440
a From Ref. 1
b Per thousand
c Number of infant deaths in a year per thousand live births
d Percentage increase in population in a yearfirst hour; and a peripheral smear revealed normocytic normo-
chromic anemia. Serum iron was 98 ng/mL; total iron binding
capacity, 420 ng/mL; and ferritin, 148 ng/mL. Blood urea was
200 mg/dL; serum creatinine, 14.4 mg/dL; electrolytes were
in developing countries. An earlier Nephrology Forumrelatively normal; serum calcium, 8.8 mg/dL; serum phospho-
rus, 6.8 mg/dL; alkaline phosphatase, 124 IU/L; and intact para- described the care of the ESRD patient in China [1]. In
thyroid hormone, 54 pg/mL. Liver function tests were normal. this Forum, I will use India as a prime example for
A chest radiograph revealed moderate cardiomegaly. Doppler addressing these issues.
ultrasonography of the carotid artery and abdominal aorta did Chronic renal failure is a devastating medical, social,
not reveal any plaques. Kidneys on ultrasound looked normal-
and economic problem for patients and their families.sized with increased echoes and two small cysts in the left lower
The availability and quality of dialysis programs largelypole. Prostate size was estimated to be 24 g with insignificant
depend on the prevailing economic conditions, the politi-residual urine. A dobutamine stress thallium test did not reveal
any reversible cardiac ischemia, and the ejection fraction was cal-social structure, overall health care facilities, and the
64%. An electrocardiogram documented left-ventricular hy- health care funding strategies of various countries. Large
pertrophy and normal rhythm. His serologic markers, including disparities separate the socio-economic structures of var-
HBsAg, HIV I and II, VDRL, anti-HCV, and IgM CMV were ious countries, especially the developed and the devel-
negative; the IgG CMV was positive. His blood group was oping countries (Tables 1 and 2) [2]. In the developedB. He was diagnosed as having end-stage renal disease, and
world, health care is generally available, whereas theoptions of renal replacement therapy were discussed with the
vast population of people living in developing countriespatient and his family. His 60-year-old wife, whose blood was
do not have access to even basic amenities like sanitationO, volunteered to be the donor. Two brothers and one sister
were diabetic and therefore not considered. Two sons, 34 years and safe drinking water. For ESRD patients in economi-
old and 30 years old, and a daughter, 32 years old, were keen cally advanced countries, the focus now is on improving
on donating, but the patient refused to accept their donating quality of life and increasing long-term survival. In
a kidney to him. His wife was fully evaluated and accepted as a marked contrast, the developing countries are grappling
donor. He received 2 injections of basiliximab and triple immu-
with short-term patient survival and the enormous costsnosuppression consisting of cyclosporine, mycophenolate, and
of therapy that limit continuation of treatment in thesteroids. He is doing well without any complications one year
majority of patients with ESRD. Most of the developingafter transplantation and has normal renal function.
world has a two-tier health care delivery system. In the
government-run non-profit hospitals, patients do not
DISCUSSION have to pay for medical advice, basic examinations, or
Dr. Vijay Kher (Senior Consultant, Department of treatment, but they must pay for disposables (gowns,
Nephrology, Indraprastha Apollo Hospitals, New Delhi, gloves, syringes, for example) and drugs. However, in
India): These two cases illustrate the great contrast in the large number of private hospitals, patients do have
and diversity of care available to patients in the devel- to pay for all services.
oping world who have end-stage renal disease (ESRD). The exact number of patients with chronic renal failure
The first case highlights the tragedy of most patients in requiring renal replacement therapy (RRT) in the devel-
the developing world who, without state funding, have oping world is not known. Unlike the developed world,
no or only meager resources for paying the recurring most developing countries lack renal registries. There-
cost of ESRD care. The second case illustrates that pa- fore, the exact incidence and prevalence of chronic renal
tients with means can avail themselves of facilities as failure in the population, its burden on the health care
good as those anywhere in the developed world. I will system, and the outcome of these patients are not known.
discuss the issues of the burden of ESRD, availability of Most of the available data, including those from the
care for these patients, estimated proportions of patients most populous countries like China and India, reflect
receiving different modalities of care, economic barriers, the collected experience from a few individual physicians
and few tertiary centers and do not reflect the situation inand costs and ethical issues involved in the care of ESRD
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Table 3. Etiology of ESRD in India
Disease, % Center Aa Center B Center C
Chronic glomerulonephritis 28.6 36.64 18.20
Diabetic nephropathy 23.2 23.84 26.76
Chronic interstitial nephritis 16.5 14.35 27.05
Hypertensive nephrosclerosis 4.1 13.47 10.06
Obstructive nephropathy 6.4 — 1.22
ADPKDb 2.0 3.53 2.07
Unknown 16.2 3.76 —
Miscellaneous 3.0 4.3 —
a Center A, Ref. 12; Center B, Ref. 14; Center C, Ref. 15
b ADPKD, autosomal dominant polycystic kidney disease
Fig. 1. First year outcome of renal replacement therapy (RRT) in
India. Abbreviations are: CAPD, continuous ambulatory peritoneal
dialysis; MHD, maintenance hemodialysis; Txp, transplant. Adapted
from Renal Failure [12].
drop out of therapy because they realize that hemodialy-
sis is not a cure and has to be performed over the long
term, and that the high cost of hemodialysis will impover-
its entirety [3]. The reported annual incidence of patients ish them [11, 12]. Approximately 9% to 13% of patients
with ESRD varies widely, from as low as 4 per million die within one year while being treated. Between 17%
population (pmp) in Bolivia to as high as 254 pmp in and 23% of patients undergo renal transplantation after
Puerto Rico [4, 5]. Barsoum reported an incidence rate being on dialysis for 2 to 3 months for pre-transplant
of 200 pmp in the Egyptian population [6]. In the rest stabilization. Although about 4% of patients remain on
of the world, the estimated incidence ranges from 100 maintenance hemodialysis (Fig. 1) [11, 12], very few stay
to 200 pmp [2]. The reasons for such wide variations on maintenance hemodialysis longer than 24 months.
are likely to be differential racial factors, environmental Only 4% of patients can pay for RRT from the pooled
conditions, the criteria used for diagnosis, and the avail- family resources, 63% take help from their employers
ability of sophisticated dialysis programs. It is evident or accept charity, 30% sell property and jewelry, and
that a vast majority of these patients die without receiv- 20% take loans [13].
ing any form of dialysis. The number of patients accepted The mean age of ESRD patients requiring dialysis in
by dialysis programs is about 80 pmp in Egypt [6], 20 most developing countries is much lower, 32 to 42 years,
pmp in Malaysia [7], 3 to 5 pmp in India [3] and China than that in the developed world, 60 to 63 years [11–16].
[1], and even lower in other countries [8]. Among the reasons for this difference are the delay in
detecting renal disease and the failure to institute con-
Hemodialysis trolling and preventive measures in patients with pro-
In India, with a population base of one billion and an gressive renal failure, both of which result in faster dete-
estimated incidence of ESRD of 100 pmp, approximately rioration of renal function and progression to ESRD.
100,000 patients develop ESRD each year. Of these, About 61% of patients with chronic renal failure present
90% never see a nephrologist. Of the 10,000 patients who with ESRD to specialists [12]. Late referrals lead to a
do consult a nephrologist, renal replacement therapy is faster progression of co-morbid conditions, increase the
initiated in 90%; the other 10% are unable to afford any cost of therapy, and worsen overall patient survival.
form of RRT [9]. India has no governmental reimburse- The relative prevalence of various primary renal dis-
ment for dialysis or transplantation, and only a small eases among patients with ESRD is highly variable in
percentage of patients with ESRD have employer spon- different countries. Chronic glomerulonephritis, diabetic
sors or health insurance that pays for RRT. Of the pa- nephropathy, chronic interstitial nephritis, and hyperten-
tients referred to a nephrologist, approximately 30% sive nephrosclerosis are the leading causes of ESRD in
India (Table 3) [12–15]. In patients between 40 and 60to 40% are critically ill and require immediate dialysis
because of symptoms that include pulmonary edema, years old, diabetic nephropathy is the most common
cause of ESRD [12]. Only 10% to 15% of patients arepericardial effusion, severe metabolic acidosis, and en-
cephalopathy [10]. biopsied, as the vast majority of patients with chronic
renal failure have bilaterally contracted kidneys by theThe majority of the 9000 patients who receive RRT
are begun on hemodialysis. Only a small proportion time they present to a nephrologist. Treatment facilities
for end-stage renal disease are not available uniformly(0.5%), usually those who are older, more affluent,
and unsuitable for transplantation, start continuous am- to all sections of society in most of the developing world.
Women, children, and the elderly bear the brunt of suchbulatory peritoneal dialysis (CAPD). Of the 8500 pa-
tients who begin hemodialysis, about 60% are lost to discrimination and are often not offered dialysis. The
number of centers providing regular dialysis servicesfollowup within three months. Presumably these patients
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varies from 1.5 pmp in the UK to 20.3 pmp in Japan the predominant causes of death in Indian dialysis pa-
tients [11, 12]. The incidence of tuberculosis in dialysis[17]. The number of dialysis units in developing countries
is not known, although published figures indicate that patients has been reported to vary between 4% and 15%
[20]. Viral hepatitis is among the most common viralthe fewest are in the large populated countries: Brazil,
3.3 pmp [5]; Algeria, 0.8 pmp [18]; China, 0.2 pmp [1]; infections encountered in dialysis patients. The incidence
and prevalence of hepatitis B viral infection varies fromand India, 0.2 pmp [3]. Approximately 68% of these
centers are in the private sector and are accessible to up- country to country. But hepatitis B vaccination among
dialysis patients, despite low seroconversion rates, hasper-income patients only. Most dialysis centers have only
2 to 4 dialysis stations, and this number is grossly insuffi- reduced the prevalence rates, from 32% to 4.7% even
among patients in endemic areas [21]. In recent years,cient for the many patients needing such facilities [3].
Moreover, a majority of the population in developing hepatitis C virus (HCV) has emerged as the primary
cause of viral hepatitis in patients undergoing regularcountries lives in remote rural areas where dialysis facili-
ties are not available. Patients and their families have dialysis therapy [22]. The prevalence varies between 16%
and 82% [23]. Nosocomial transmission has been demon-to travel long distances and, in many instances, have to
be relocated with a resultant loss of livelihood. India has strated in dialysis units. Therefore, strict enforcement of
screening and infection control measures for preventionabout 600 nephrologists, 300 to 400 dialysis units, and
1000 dialysis stations, with more than 70% of these in of transmission of HCV infection in dialysis patients
must be instituted until an effective vaccine becomesthe private sector [9]. Patients assigned to hemodialysis
are usually dialyzed only twice weekly, each session last- available. There is one bit of good news: HIV infection
has not yet been reported to be a major problem in theing 3 to 4 hours. Patients usually are dialyzed on cellulosic
membranes with a surface area of 1.0 to 1.3 m2 at blood dialysis population in developing countries [24].
Malnutrition afflicts most patients on dialysis in devel-flow rates of 200 to 300 mL/min using 16 G fistula needles.
Acetate dialysate is used in more than 70% of patients oping countries; the reported frequency is 44% to 77%.
The imposition of protein restriction in patients who arefor economic and technical reasons. The dialyzer and
tubing are reused together four to six times, with manual already on a calorie-deficient diet, delay in initiation of
dialysis, and delivery of inadequate dialysis contributereprocessing using formaldehyde for disinfection.
In India, the prescription for hemodialysis typically is to this problem. In fact, protein malnutrition increased
in one study following initiation of dialysis in as manyempiric. Data on adequacy of such dialysis schedules are
not available. Rao et al reported a short study indicating as 86% of Indian patients [25].
The pattern of renal osteodystrophy in the developingthat KT/V was less than 1 in about 50% of the hemodialy-
sis sessions studied. Higher KT/V and urea reduction countries also differs from that in the developed world.
In a few studies from our country, osteitis fibrosa orratios (URRs) were associated with smaller body size,
use of arteriovenous fistula rather than a venous access, hyperparathyroidism was observed only in 30% of pa-
tients, and most others had mixed bone disease, ady-and higher dialyzer-to-body-surface-area ratio [19]. The
assumption that a satisfactory KT/V and time-averaged namic bone disease, or osteomalacia [26, 27]. Empiric
use of active vitamin D analogs without documentationconcentration (TAC) of urea can be achieved in Indian
ESRD patients with twice-weekly dialysis needs to be of parathyroid status carries the risk of further suppres-
sion of bone turnover.tested in rigorous clinical trials. In my view, most patients
continue to suffer from uremic symptoms on such dialysis
Continuous ambulatory peritoneal dialysisschedules, and long-time survivors are few and far be-
tween. There has been a significant improvement in Continuous ambulatory peritoneal dialysis is becom-
ing the preferred modality of dialysis in countries withcountries where governments have earmarked separate
funds for dialysis as in eastern European countries [8]. limited resources. Nissensen et al observed that countries
with fixed annual health care budgets to hospitals orIn most Indian centers, water treatment, if any, con-
sists only of de-ionization. Often water analyses are not regions have a higher usage of CAPD because of its
cost-effectiveness [28]. An increasing number of patientsperformed before one decides on the water treatment
required. In only a few centers is water treatment appro- are utilizing CAPD in the UK, New Zealand, and Aus-
tralia, where government-funded hospitals provide dial-priate, with activated charcoal and reverse osmosis. Wa-
ter testing facilities do not exist everywhere. Water qual- ysis services. The procedure does not require expensive
equipment, and after the initial training period, theity is tested infrequently or never.
In underdeveloped countries, a combination of poor patient no longer requires regular visits to the dialysis
center. Thus, CAPD offers greater independence andliving conditions, inadequate dialysis, malnutrition, hy-
poalbuminemia, and frequent blood transfusion makes mobility as well as a better quality of life compared
to hemodialysis. These qualities should make CAPDdialysis patients prone to a variety of bacterial, viral, and
fungal infections. Infection and cardiac diseases remain the ideal modality for ESRD patients in developing
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countries. However, utilization of CAPD varies greatly Renal transplantation
among the developing countries. In some South Ameri- In the absence of adequate dialysis facilities, renal
can countries like Mexico, Venezuela, and Brazil, 50% transplantation remains the only hope of survival for
to 90% of dialysis patients are on CAPD. Its use in other ESRD patients in developing countries. In contrast to
developing countries like China and India is low. In developed countries, the underdeveloped nations have
contrast to that in the developed world, the cost of CAPD no organized cadaver transplant program. Utilization of
is two times higher than that of hemodialysis in devel- cadaveric kidneys is poorly organized in Asian countries;
oping countries. The main reason for this disparity is the most of these countries do not have an organ procure-
lack of indigenous facilities to manufacture peritoneal ment organization, with the possible exception of Singa-
dialysis fluid [29]. pore and Hong Kong. In India, despite the organ trans-
In India, CAPD is reserved as the last option for most plant bill having been passed in 1994, no organ sharing
patients with ESRD. Patients not suitable for trans- network has been established. The meager cadaver trans-
plantation and those who can afford peritoneal dialysis plant activity in the country and the process of procure-
are offered this modality of treatment. The nephrologist ment and transplantation depend on the initiative of
heavily influences this decision. Poor patients often are individual transplant physicians and the crucial role of
not even informed of the peritoneal dialysis option, as cooperating intensive care units. Insufficient education
the nephrologist may deem it beyond their economic of health care professionals and the general public re-
means [9]. Initially there was a fear that CAPD would garding cadaver donations plays an important role in the
not do well in India given the hot, humid, and unhygienic low organ procurement rate in these countries. Although
conditions along with low levels of literacy and educa- cultural and social barriers to cadaver organ procure-
tion. However, the documented low incidence of perito- ment exist in various countries, none of the major reli-
nitis comparable to that in developed countries might gions offers any impediment to cadaver donation or or-
be related to India having a highly selected population gan transplantation.
on CAPD, usually the affluent, educated, and those who About 2500 to 3000 renal transplants are performed
live in a hygienic environment. As the modality extends in India each year [31]. India has approximately 100
to a wider cross-section of the population, there is a transplant centers, and more than 75% of these are in
potential for poorer results. the private sector. Of the 3000 transplants, only about
Patients on CAPD are usually dialyzed with 3 ex- 100 are of cadaveric origin. Living unrelated donors ac-
changes per day of 2 liters each. This prescription is based count for 50% to 60% of transplants, and the rest are
on the assumption that 3 exchanges provide adequate from living related donors [31]. The typical waiting pe-
dialysis in Indian patients with small frames and low riod for transplantation is 2 to 3 months but can be as
protein intake. However, no data from the country sub- long as 6 to 12 months. Preemptive transplantation has
stantiate this. Limited data on adequacy of peritoneal been advocated as a method for improving the cost effec-
dialysis exist in India [30]. The straight two-cuffed Tenck- tiveness of transplantation [32]. Reducing the duration
hoff catheter is used predominantly. Most units use a on dialysis prior to transplantation is another method of
break-in period of 2 weeks. The training is often provided reducing the cost of transplantation [33]. This practice
by nurses or CAPD nurse coordinators and usually lasts is possible in cases of living donor transplants, in which
for 3 to 7 days. Hospital administrators are reluctant the donor and recipient workups can be completed be-
to invest in peritoneal dialysis, as they believe that the fore the patient becomes dialysis-dependent. Another
remuneration to the hospital is limited. Most CAPD strategy for reducing the cost of long-term immunosup-
patients use the Y-set, and less than 10% of patients use pression is to use cyclosporine A for a limited period of
the twin bag disconnect system; only the select affluent 6 to 12 months only and continue maintenance immuno-
use a cycler. The incidence of peritonitis ranges from suppression with low-cost azathioprine and steroids [33].
one episode in 28 months to one in 54 months. The But this strategy has been successful only in living related
incidence of exit site and tunnel infections is low, as transplants with good HLA matching in comparison to
patients generally do not remain on CAPD for longer living unrelated transplants, in whom the outcome is
than 2 years. Fewer than 10% of patients switch to main- poor following cyclosporine withdrawal [34]. Some units
tenance hemodialysis. The rest discontinue therapy be- have been able to cut cyclosporine A dosage with the
cause of economic considerations, “burn-out,” or recur- concomitant use of ketoconazole [29]. However, the cost
rent peritonitis, or they are lost to follow-up or die. In of more frequent blood cyclosporine monitoring might
short, CAPD is currently considered the therapy for the offset the economic advantage of this strategy. Only a
rich and the elderly (over age 60). The growth of the select few affluent patients can afford the newer immu-
modality is hampered by its cost and not by the percep- nosuppressive drugs like tacrolimus, mycophenolate,
or interleukin-2 receptor antibodies. The long-termtion that it is technically inferior to hemodialysis.
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follow-up of transplant patients is usually good, as pa- laxis is controversial; it has not been shown to be of any
tients worry about rejections and having to revert to benefit in endemic areas [47]. Drug-resistant strains are
dialysis. Still, noncompliance because of financial burden also of concern; the incidence of primary INH resistance
of the cost of continued immunosuppressive medication is increasing steadily [48]. Routine INH prophylaxis is,
does affect the outcome of these patients. therefore, not recommended in endemic areas [20].
Infections complicate the course in 50% to 75% of Other common infections in post-transplant patients
transplant recipients in developing countries, with mor- are hepatitis B virus and hepatitis C virus disease, both
tality ranging from 20% to 60% [35–39]. In comparison, being highly prevalent in dialysis patients [49–51]. Cyto-
developed countries have an incidence of infection of megaloviral infection has increased from 4% in the pre-
about 40%, and advances in diagnosis, prevention, and cyclosporine era to 17% in the cyclosporine era in one
therapy have reduced mortality to less than 5% [40, 41]. autopsy series [20]. Opportunistic fungal infections occur
The factors responsible for the high incidence of these in 4% to 7% of recipients, but these carry a high mortality
infections and dismal outcome are unhygienic condi- rate of over 65% [38, 52]. Malaria and leishmaniasis are
tions, late presentation and diagnosis, and the high cost also encountered [53–55].
of life-saving antimicrobial agents. Sensitive and specific
diagnostic tools such as tissue biopsy, antigen detection, Cost of renal replacement therapy
polymerase chain reaction, and culture of unusual bacte- The cost of a hemodialysis session in India ranges from
ria, fungi, and viruses routinely available in the west are $20 (US) to $40 including the procedure cost and the
either not available or are too expensive [20]. cost of disposables (dialyzer, blood lines, concentrate,
Autopsies are not done, and the cause of death re- etc.). Many hospitals and satellite dialysis clinics do not
mains unknown in the vast majority of these patients. make money from hemodialysis and can incur losses.
Since most patients cannot afford long-term mainte- The cost of establishing an arteriovenous fistula ranges
nance dialysis or a second transplant in the event of graft from $15 (US) in government hospitals to $150 in private
loss due to rejection, immunosuppressive therapy is often centers. The cost of erythropoietin is approximately $400
continued even in the presence of severe infection. Ther- per month. As a consequence, only 30% of Indian hemo-
apy further lowers the immune status and increases the dialysis patients receive erythropoietin therapy. In the
patient’s chances of developing superimposed infections US, the cost of erythropoietin constitutes approximately
with other opportunistic organisms. Because of these 10% of the cost of dialysis. In India, erythropoietin costs
factors, patient survival is synonymous with graft survival are as much as twice the cost of dialysis.
in India and most of the developing world.
The cost of each CAPD exchange using the Y-set is
Tuberculosis affects 10% to 13% of renal transplant
around $5 (US). Based on 4 daily exchanges, the monthlyrecipients in India. Renal transplant recipients with tuber-
cost is $600. The monthly cost of hemodialysis is $300.culosis present numerous diagnostic difficulties [42–44].
The monthly cost of CAPD is, therefore, twice the costThe Mantoux test is generally unhelpful, classic radio-
of hemodialysis. The cost of CAPD access ranges fromlogic findings are seen only in a minority, identification
$50 in government hospitals to $400 in private hospitals.of acid-fast bacilli in a sputum smear has a low yield,
However, the monthly cost of erythropoietin can be lessand culture takes 4 to 6 weeks. Bronchoalveolar lavage,
in conjunction with CAPD because of lower doses re-bone marrow biopsy, and liver biopsy have to be utilized
quired.to make a diagnosis of tuberculosis [42]. Treatment of
The cost of transplant procedures varies from $1500tuberculosis also presents problems with the choice of
(US) in government hospitals to as much as $7000 inantituberculous drugs and duration of therapy. Rifampi-
private hospitals. The cost of immunosuppressive ther-cin is a well-known hepatic P-450 microsomal enzyme
apy is around $3000 for the first year, although it caninducer that increases the clearance of both prednisolone
decline to as little as $300 per year thereafter if onlyand cyclosporine A. The dose of cyclosporine needs to
azathioprine and steroids are used. However, as cyclo-be increased three- to fourfold to maintain therapeutic
sporine is often continued in many patients beyond theblood levels. This increase raises the cost of therapy
first year, the recurring annual cost of immunosuppres-and is unacceptable to the vast majority of patients. The
sion can reach $3000. From among the 3 RRT optionsalternative regimen that has been successfully utilized
available, renal transplantation is the preferred courseconsists of a combination of isoniazid, ethambutol, pyra-
because it is the most cost-effective and associated withzinamide, and ofloxacin or ciprofloxacin [45]. The opti-
the highest quality of life (Table 4). The Indian 2-yearmal duration of therapy is a matter of debate. Combina-
budget for transplantation is considerably less than thattions with rifampicin and INH have been recommended
for hemodialysis and CAPD. Thus, renal transplantationfor 9 months [45]. However, the duration is increased to
is the preferred modality, provided a suitable donor is18 months in patients who are taking cyclosporine and
not receiving rifampicin [46]. The role of INH prophy- available. Still, resource constraints can compromise the
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Table 4. Comparison of costs for three RRT options number of exchanges on CAPD. Although clearly aware
that inadequate dialysis will have a negative impact onCost 1st year 2nd year Total
a patient’s well being and quality of life, nephrologistsRenal transplantb 8900a 3000 11,900
Hemodialysisc 8500 8400 16,900 are unable to enforce compliance, as patients’ finances
CAPDd 9900 9600 19,500 dictate the frequency and duration of RRT.
a US dollars A marked shortage of donor kidneys, the lack of a
b Pre-Tx HD  3 months ($900), surgery ($5000), immunosuppression ($3000)
good cadaver program, and large-scale poverty have ledfor one year
c Hemodialysis 2 times weekly including twice-weekly EPO and the cost of to trafficking in organs [31]. Several aspects of this issue
access
have been reviewed in a recent Nephrology Forum byd CAPD 4 exchanges/day and the cost of access
Hou [56]. In the context of affluent societies, with high
standards of social justice and widespread availability of
health care, organ commerce was swiftly rejected and
immunosuppressive regimen and thus jeopardize graft banned by law in most Western countries. However,
survival. in the developing countries, poverty and lack of legal
The annual cost of RRT is more than 10 times the restrictions encourage people to sell their kidneys. It is
per capita gross national product (GNP). In developed estimated that 50% to 60% of kidneys transplanted in
countries like the US, the annual cost of RRT is about India come from living unrelated donors [31]. In spite
twice the per capita GNP, and 80% of the costs are of an organ transplant act having been enacted in 1994
reimbursed by the government. Given the high cost of that bans the sale of organs, a large number of renal
RRT, should the Indian government pay for RRT? In transplants from living unrelated donors who sell their
1994-95 the total health care budget in India was approxi- kidneys are still being done in India [57]. Many recipients
mately $2.3 billion (US). If we assume a reimbursement of such kidneys belong to affluent nations who come to
rate of 80% and an annual cost of hemodialysis of $8400 India for organ transplantation. The ethical aspects of
including the cost of EPO and assuming 100,000 patients, commercial living unrelated transplants have been de-
we come up with a reimbursement budget of 670 million, bated widely in the media as well as in the transplant
or 25% of the total health care budget for only 0.01% community [31, 58–60]. The outcome of live unrelated
of the population. Obviously this is inequitable and not transplants has been reported to be good, and 5- and
justifiable [9]. The same resources can provide long-term 10-year survival rates are better than those for cadaver
benefits to a much larger segment of the population by transplants [61–63]. The risk of graft loss was 16% lower
being assigned to more urgent and needy areas, such in living unrelated transplants compared with cadaver
as infant and maternal mortality, immunization, acute kidney transplants [61]. The other argument in favor of
gastroenteritis, malnutrition, improved water and sanita- such transplants was the reduction in time spent on dial-
tion, and communicable diseases like tuberculosis and ysis with a consequent improvement in quality of life
malaria. and, as or more important, the reduction in treatment
costs.
Ethical issues In view of such observations, arguments have been
The high cost of RRT in the non-state-funded infra- advanced for a revival of living unrelated renal trans-
structure in the developing countries poses many ethi- plantation. Between 1994 and 1996, the number of such
cal dilemmas. Nephrologists are faced with the ethical transplants doubled in the United States [64]. The do-
dilemma of whether it is appropriate to start RRT nors, however, were individuals who, although not genet-
in a patient whose resources are limited and who will ically related, had close emotional ties with recipients,
most probably discontinue therapy and die after deplet- such as a spouse, close friend, or a partner. To differen-
ing all family resources and savings. Should such patients tiate such donors from paid unrelated donors, these
not be discouraged from starting RRT? Nephrologists donors have been termed “emotionally related living
may agree that it is inappropriate to initiate RRT in kidney donors.” Transplants from “emotionally related”
patients who cannot afford it or who have no secondary donors currently are considered acceptable in many cen-
source of payment. However, in many instances (or, as ters in the world [65]. In the context of the large economic
a general rule) the patient’s family is initially willing to inequities and poverty in the developing world, however,
make any sacrifice necessary to preserve life. Thus, differentiation of “emotionally related” and paid unre-
strong emotions of the patient’s family sometimes force lated transplantation has obvious difficulties [66]. More-
the nephrologist’s hand against his or her better judg- over, exploitation of poor donors by middlemen in these
ment. It is only in the long term that the reality dawns countries, who grab the major part of the sale’s profit,
and emotions and resources are exhausted. The nephrol- makes the whole process murkier [31]. Other examples
ogist is also helpless when patients become noncompliant of unconventional commercially exploited donor sources
are executed prisoners in China and “farming” of kidneysand start missing hemodialysis sessions or decrease the
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from inmates in a psychiatric hospital in Argentina mortality [69], but 4% of donors experienced complica-
tions in the immediate postoperative period. The study[67, 68]. Advocates of transplantation using sold kidneys
argue that if donors are carefully selected, a middleman did not include any long-term follow-up of these donors
[69]. Several examples of ESRD in living donors haveis not involved, and the operation is performed in a good
hospital, the transplant will benefit both the recipient been documented [62]. Although most long-term studies
on living donors have not found any adverse impact onand the donor, who needs the money [69]. In reality such
transplants currently are done in back-street clinics and blood pressure, proteinuria, or survival, there is a con-
cern about the health of the donor. Broumand reportedlead to death in a large number of donors and recipients,
and those who do survive end up with transmitted dis- that 95% of living unrelated donors received no follow-
up visits in Iran [77]. In a study on motivation of unre-eases such as hepatitis and AIDS [70, 71]. It has been
argued that it is possible to have laws and professional lated paid Iranian donors, 82% were unsatisfied with
their donation, 75% did not achieve their goals for sell-practices that allow selling of nonvital organs for trans-
plantation. Lu has constructed a framework for sale of ing, 76% agreed that the sale of kidneys should be
banned, and, if given another chance, 99% would begkidneys from living donors that has been modified by
Barry [72]. The modified framework suggests that all or take a loan instead of selling a kidney [78].
It has been argued that the continued use of livingparties involved are citizens of the same country; no
brokers or contractors are allowed; the donor and recipi- unrelated renal transplants will alleviate the donor short-
age, especially in countries where cadaver programs areent are unknown to each other; a non-profit agency or
voluntary organization (such as the United Network for not in place. But these hopes have not been realized.
Data from a center in Iran show that even though theOrgan Sharing or Red Cross) oversees the transaction;
an algorithm to ensure the physical and mental health number of living unrelated renal transplants increased
from one in 1987–1988 to 70 in 1991–1992, the totalof the donor and prevent disease transmissions is fol-
lowed; the donor and recipient have independent teams number of transplants remained unchanged. In fact, that
of physicians; and long-term care for health problems the number of living related transplants decreased from
arising from donor nephrectomy is provided for the do- 91 to 26 in the corresponding periods suggests that living
nor [72]. unrelated renal transplants had increased at the expense
Putting the ethical debate aside, let’s examine the re- of living related transplants. In other words, once living
sults of paid unrelated donor transplants in the devel- unrelated renal transplants were permitted, all those who
oping countries and compare these results with unrelated could afford to pay opted for a kidney from that source
donor transplants from the developed world, as well as rather than subjecting their kith and kin to the risk of
transplants performed in the same center without the donor nephrectomy. It has been suggested that granting
involvement of commercial donors. Salahudeen et al re- official sanction even to “emotionally related” living re-
ported an 18.5% one-year mortality rate among a group nal donor transplantation is likely to result in a slippery
of 130 patients from United Arab Emirates and Oman slope that would ultimately culminate in commercial
who underwent living unrelated renal transplants in In- transplants being performed in developing countries. I
dia [70]. About 64% of deaths occurred within the first have attempted to highlight the problems, the difficulties,
3 months. The major cause of death was infection: 5.4% and the barriers to providing RRT services in the devel-
of the patients tested positive for HIV or HBsAg after oping world. One hopes that while answers to the many
the transplant. The authors speculated that some of these questions raised are being sought, some, if not all, the
infections could have been transmitted through contami- barriers to RRT options in these countries would be
nated allografts and/or blood products used during the removed.
perioperative period. The one-year patient survival
among those whose kidneys came from living related
QUESTIONS AND ANSWERSdonors at their own center during that time was 98%
Dr. Nicolaos E. Madias (Executive Academic Dean,[70]. Several other workers reported similar results
Tufts University School of Medicine, Boston, Massachu-among living unrelated transplants performed in many
setts, USA): You outlined formidable barriers to renalcountries including India, Iraq, Macedonia, and Estonia
replacement therapy and indicated that renal trans-[71, 73–75]. Berkman and coworkers noted a higher inci-
plantation is the most cost-effective therapeutic mod-dence of Pneumocystis carinii pneumonia among pa-
ality. In other countries, organized efforts have yieldedtients returning to Israel after receiving living unrelated
a gradual increase in cadaveric transplantation. Couldrenal transplants in Iraq and India [76].
you please outline the views of the Indian Society ofOne important concern is the risk to the donor. Is
Nephrology on these issues and tell us what measuresthere a greater risk to paid unrelated donors? We have
are being taken to educate health care professionals andlittle data on the donors from centers where such trans-
plants are done. One study from India reported no donor the public about kidney donation?
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Dr. Kher: The organ transplant act by which brain nephrologists intensely lobbying the US Federal govern-
ment in the early 1970s.death criteria were legalized in our country was passed
Dr. Bharat Shah (Head, Department of Nephrology,in 1994. Since then, we have discussed these issues at
Hinduja Hospital, Mumbai, India): Dr. Kher, you men-Indian Society of Nephrology meetings, but no organized
tioned that ESRD is seen at a younger age in our popula-effort has been made by the Society to educate health
tion than in the developed countries. Why is that so?care professionals and the public at large. The National
Diabetic nephropathy is a common cause of ESRD inKidney Foundation in Singapore has done remarkably
our country, and most of those patients have type 2well both in the field of public education as well as in
diabetes. These people develop nephropathy at a lateproviding cost-effective RRT to its ESRD patients. I
age, so I would have expected the mean age of ESRDbelieve that the Indian Society of Nephrology is the
patients to be older.powerful forum that needs to address these issues head
Dr. Kher: The data from Vellore, Lucknow, andon and initiate organized efforts in this direction on the
Chandigarh reveal the mean age of ESRD patients topattern of the NKF in Singapore.
be 38.6 years, 43.0 years, and 42.0 years, respectively [11,Dr. John T. Harrington (Dean, Tufts University
12, 14]. Even for those with diabetic nephropathy, theSchool of Medicine): If 25% of Indian health care dollars
mean age from the three centers was 52.5, 51.2, and 50.4were to be used for only 0.01% of the patient popula-
years, respectively. These ages are all much lower thantion—and obviously that is not possible—why not restrict
those reported from the West (average, more than 60dialysis to patients with acute renal failure and to patients
years). The reasons why ESRD affects Indian patientsawaiting transplantation?
at a younger age are not clear. My guess is that earlyDr. Kher: In fact, in public funded hospitals, dialysis
onset of ESRD is due to a delay in our detecting theis provided only to patients with acute renal failure and
renal disease and our failure to institute preventive orto patients awaiting transplantation. However, most pa-
corrective measures. These deficiencies result in fastertients in private institutions choose the type of renal
deterioration of renal function and progression toreplacement therapy depending on their ability to pay
ESRD. This should be true for diabetics as well. Offor it. In India, more than 70% of RRT facilities exist
all patients with CRF, 61% present with ESRD. Latein private institutions.
referrals also lead to faster progression of comorbid con-Dr. K. S. Chugh (Professor Emeritus, Post Graduate
ditions, increase the cost of therapy, and worsen overallInstitute of Medical Sciences and Research Centre, Chan-
patient survival.digarh, India): What strategies would you recommend
Dr. Madias: Quite paradoxically, you indicated thatto make cadaveric donors more popular? According to
CAPD is the least frequent modality of renal replace-
official figures, approximately 60,000 roadside accidents
ment in India because of its cost, whereas CAPD is very
occur yearly; why can’t we make good use of the organs common in other poor countries because it is much more
available from these accident victims? affordable. Could you comment on the reasons for the
Dr. Kher: In India, we need to improve the infrastruc- excessive cost of CAPD in India and measures that need
ture for quick and safe transportation of accident victims. to be taken to resolve this important problem?
We need mobile vans with resuscitation facilities and at Dr. Kher: The main reason for the excessive cost of
least one hospital in each district that has ventilatory CAPD is that the peritoneal dialysis cyclers, fluid, and
facilities for taking care of these patients. Currently, we bags, along with all the accessories, have to be imported.
are not able to convince the families of even 10% of This is also true for hemodialysis machines, hemodialyz-
brain dead patients in hospitals of major metropolitan ers, and blood tubing, and drugs like cyclosporine and
cities to donate organs. To improve this situation, we erythropoietin. Local manufacture of all these items is
need to initiate a multi-pronged approach for educat- within the technologic capabilities of Indian industry.
ing professional health care workers as well as the pub- Limiting the investment in these products is the low
lic through media, religious congregations, schools, and demand in India for them. However, if manufacturing
colleges. The Indian Society of Nephrology should spear- facilities are planned to serve local as well as export
head this campaign aggressively and make it target-ori- markets, and the Indian Society of Nephrology lobbies
ented. We have in the Indian Society influential person- the government to provide incentives for such invest-
nel who can use social, political, and other pressures at ment, local manufacture can become a reality. Consider-
the governmental level to bring this program to fruition. able cost savings might accrue, allowing a larger segment
Dr. Harrington: Despite the absence of national of the ESRD population access to RRT.
health insurance in the US, the federal Medicare system, Dr. Ronald Jones (Professor of Nephrology, Govern-
which pays health care costs for the elderly, does pay ment MK Medical College, Salem, India): Some of our
for treatment of patients with ESRD. Implementation patients who cannot afford regular dialysis and do not have
a suitable donor remain on conservative managementof this payment system was brought about by American
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and undergo hemodialysis once weekly for 5 hours. What patient. One must accept the lesser of two evils and make
compromises. It is extremely taxing to manage theseis your recommendation for protein intake in these pa-
tients? difficulties day in and day out.
Dr. H. S. Ballal (Director, Manipal Institute of Ne-Dr. Kher: Obviously, these patients are underdialyzed
and will suffer the consequences of uncontrolled azote- phrology and Urology, Manipal Hospital, Bangalore, In-
dia): Could you speculate on the reasons for the highmia, with loss of appetite and vomiting. Whatever pro-
tein is prescribed for these patients, they are unable to incidence of chronic interstitial nephritis as a cause of
ESRD in India?eat because of anorexia. Their survival rate is extremely
poor. You lose them as much as a consequence of compli- Dr. Kher: Chronic interstitial nephritis was the most
common (27%) cause of renal failure in Dr. Mani’s seriescations of azotemia as of malnutrition. In India, the prob-
lem of severe malnutrition is rampant among dialysis [15] and it accounted for 16.5% of patients in our series
[13]. This observation is in contrast to an incidence ofpatients, largely because of unnecessary protein restric-
tion in a population consuming low amounts of protein 3% in USRDS data. The causes of chronic interstitial
nephritis have not been elucidated in the series I men-in their standard diets. Slowing or retarding progression
of renal failure would no doubt be a desired goal but not tioned. Analgesic abuse is uncommon in India. Indige-
nous drugs, food additives, pesticides, or other chemicalsat the cost of severe malnutrition, which has devastating
effects. (not strictly regulated and monitored in our country)
have been suspected as incriminating agents [13, 15]. ButDr. Madias: Although you did not indicate whether
there is a differential gender distribution of ESRD pa- we have no proof for this.
Dr. Madias: Dr. Remuzzi’s group, in collaborationtients, you mentioned a great disparity of the two sexes
in receiving kidneys (male predominance) and donating with Bolivian nephrologists, has carried out an extensive
screening effort in Bolivia to identify patients at highkidneys (female predominance). Could you please com-
ment on this disparity? risk for renal diseases. I think it will be important to
engage general practitioners in screening the populationDr. Kher: Most studies from our country have re-
ported a male preponderance (70%) in the ESRD popu- at large to identify such patients and then institute mea-
sures to delay progression.lation. These are hospital-based studies and reflect the
bias that males are more often brought to the hospital for Dr. Kher: To tackle the problem of limited access to
RRT, an important method would be to try to reduce thetreatment. This phenomenon is also reflected in hospital
admissions and hospital attendance, which is also around incidence of ESRD and the need for RRT by preventive
measures. Diabetes and hypertension are major risk fac-70% male [15]. We have no reason to assume that a
differential exists in the gender distribution of ESRD in tors for renal failure. In a survey of a rural community
of 25,000 people of all ages in southern India, Dr. Manithe Indian community. However, there is a great dispar-
ity in the provision of RRT in India. Women, elderly documented that 7.5% of the population was at risk of
developing renal failure [13]. Early detection and treat-persons, and small children bear the brunt of such dis-
crimination. ment can reduce the incidence and slow the progression.
A major countrywide initiative by governmental andDr. A. R. Dutta (Chief Nephrologist, Wockhardt Hos-
pital and Kidney Institute, Kolkatta, India): Dr. Kher, the non-governmental organizations to screen the popula-
tion at large would yield benefits that should fully justifypatients whom you discussed represent two extremes,
and decisions are relatively easy. It is the middle segment the costs.
Dr. S. Sundar (Director and Chief Nephrologist, Kar-where decisions are difficult. How does one balance dial-
ysis prescription and outcome with economic realities, natka Nephrology and Transplant Institute, Lakeside
Hospital, Bangalore): Despite the organ transplant actfor example, twice a week hemodialysis with erythropoi-
etin versus thrice-a-week dialysis without erythropoietin, that was passed in 1994, cadaveric organ donation is
infrequent. Since most patients cannot afford dialysis,or less “safe dialysis” versus more “unsafe dialysis?”
Dr. Kher: It is like being between the deep sea and the and renal transplantation is the most cost-effective treat-
ment, should we not legalize organ sale and allow it todevil. The nephrologist practicing under hard economic
realities always faces such a dilemma. There is no easy be done openly under strict guidelines, rather than let
it be done in the back-street nursing homes and smallsolution or formula to balance a dialysis prescription in
such situations. One tries to optimize for each patient hospitals clandestinely?
Dr. Kher: You have touched on a highly debated issueindividually. For example, somebody with reasonable
residual renal function might do well with twice-a-week in this and other developing countries. Arguments in
favor of paid organ donation are no doubt appealing,dialysis, whereas another patient with anemia and iron
deficiency could show improvement in hemoglobin with and the framework for the sale of kidneys from living
donors as suggested by Lu and modified by Barry [72]intravenous iron itself and not require erythropoietin.
There is no doubt that it is a tightrope walk with each also seems to be a better alternative than uncontrolled,
Nephrology Forum: ESRD in developing countries360
clandestine, unrelated, paid renal transplantation. How- tion test to guide therapy prescription, and use of optimal
fill volumes and dextrose concentrations. Better and im-ever, the developing countries have enormous socio-eco-
nomic and regulatory differences from Western nations. proved protocols for early detection and treatment of
acute rejection, better monitoring of cyclosporine level,My worry is that the voluntary and even legislative guide-
lines are likely to be ignored in a society where the and ensuring patient compliance should lead to better
outcomes in renal transplantation. These methods shouldinvolved institutions are not yet strong enough, the rele-
vant laws are in a state of flux, the number of transplants not require major investments of funds and would im-
prove the quality and outcome of RRT modalities.is grossly inadequate to cope with the number of patients,
the distribution of wealth is skewed with massive wealth Dr. Harrington: What is the average survival of trans-
plant patients in India, and what percentage lose theirjuxtaposed to dire poverty, and both petty and major
corruption exists at all levels of society. In spite of these kidney because they stop taking immunosuppressive
medication?caveats, the Indian Society of Nephrology should hold
an open debate on these issues. The problem of paid Dr. Kher: One- and 5-year survival after renal trans-
plantation averages around 93% and 71% in related,unrelated transplants is ours. Only we can and should
find its solution. and 85% and 66% in unrelated, transplants, respectively
[34]. One- and 5-year survival after renal related trans-Dr. Vincent Lloyd (Associate Professor and Head,
Department of Nephrology, St. John’s Medical College plantation in my hospital (a private facility) is 96% and
84%, respectively (unpublished data). Many transplantHospital, Bangalore): Generic cyclosporines introduce
an approximate 40% cost reduction in the post-trans- recipients, especially those in the government-funded
hospitals, discontinue taking cyclosporine after 9 to 12plant period. Would you advocate the use of generic
cyclosporine? months and are given dual therapy, prednisolone and
azathioprine, because of cost constraints. The percentageDr. Kher: Each one of us looks for methods of cutting
costs of treatment while working under severe financial of patients who lose their graft because of stopping im-
munosuppression is not known. About 30% of transplantconstraints. Although generic cyclosporines do provide
cheaper alternatives, concerns about equivalence and recipients cannot afford to continue cyclosporine beyond
one year. My guess is that about 10% to 15% of patientsefficacy need to be sorted out. Many poor patients refuse
to accept generic drugs without evidence about their lose their grafts because they stop taking immunosup-
pressive medications.equivalent efficacy. The treating physician also needs to
feel equally confident about the generics. Dr. Mohan Rajapurkar (Medical Director, Muljibhai
Patel Urological Hospital, Nadiad, India): Most of ourDr. Brian Pereira (Professor of Medicine, Tufts Uni-
versity School of Medicine): What will be the effect in patients on maintenance dialysis are awaiting trans-
plantation. Do any data prove that so-called “adequate”India on the cost of immunosuppressive medications
postimplementation of World Trade Organization (WTO) dialysis gives better outcomes in renal transplantation?
Dr. Kher: It is a well-accepted fact that adequateregulations?
Dr. Kher: India has agreed to the WTO regulations, dialysis improves nutritional status and overall outcome
of patients. Most of our patients are severely uremic andand I would guess that already expensive immunosup-
pressive medications will become costlier. However, one malnourished by the time they start dialysis. Inadequate
dialysis further aggravates their malnutrition, as docu-hopes that the recent opening up of the insurance sector
to multinational companies will result in policies and mented in a study from Vellore [25]. Malnutrition is an
important determinant of poor outcome in dialysis asschemes that provide reimbursement for RRT, benefit-
ing at least a large proportion of our middle class popula- well as in transplantation. The usual belief that Indians
require less dialysis, and thus twice-a-week dialysis or 3tion.
Dr. Vivekanand Jha (Associate Professor of Nephrol- exchanges/day on CAPD are adequate, is not borne out
by any scientific data.ogy, Post Graduate Institute of Medical Education and
Research Centre, Chandigarh): Improvement in the de- Dr. Harbir Kohli (Associate Professor, Department
of Nephrology, Post Graduate Institute of Nephrology,livery of RRT requires investment of money, which is
not readily available. Is there a way for us to improve Chandigarh): How reliable is the estimate of 100 patients
with CRF per million population for India? What is thethe quality of RRT without major investments of funds?
Dr. Kher: There is room for improvement in the qual- source of this estimate?
Dr. Kher: No validated data are available from ourity of all modalities of RRT currently being delivered.
Hemodialysis patients can benefit from improved dial- country. The figure of 100 patients per million population
is a presumptive estimate based on data from majorysis prescriptions, better water treatment, better re-
processing of dialyzers, and correction of iron deficiency tertiary care referral centers in the country. In a study
from the UK, which compared the incidence of ESRDby optimal use of erythropoietin. For CAPD patients,
we need better training, use of the peritoneal equilibra- among immigrant Indo-Asians in two health districts of
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13. Mani MK: The management of end stage renal disease in India.London and Leicester, patients with ESRD accounted
Artif Organs 22:182–186, 1998
for 115 and 123 per million population compared to 21.5 14. Sakhuja V, Jha V, Ghosh AK: Chronic renal failure in India.
Nephrol Dial Transplant 9:871–872, 1994and 43 among the local whites [79]. I feel strongly that
15. Mani MK: Chronic renal failure in India. Nephrol Dial Transplantour figures are underestimates and that the incidence of
8:684–689, 1993
chronic renal failure is likely to be much higher than 100 16. Kumar H, Alan F, Naqvi SA: Experience of hemodialysis at a
kidney center. J Pak Med Assoc 42:234–236, 1992patients per million population.
17. D’Amico G: Comparability of the different registries on renalDr. Manoj Singhal (Senior Consultant in Nephrol-
replacement therapy. Am J Kidney Dis 25:113–118, 1995
ogy, Indraprastha Apollo Hospital, New Delhi, India): 18. Salah H: An overview of renal replacement therapy in Algeria.
Saudi J Kidney Dis Transplant 5:190–192, 1994In your opinion, what are the three most important areas
19. Rao M, Juneja R, Jacob CK: Empiric prescription hemodialysis.that you would recommend be implemented in India?
Is there room for improvement? Indian J Nephrol 8:12–16, 1998
Dr. Kher: These would be a national ESRD registry, 20. Jha V, Chugh S, Chugh KS: Infections in dialysis and transplant
patients in tropical countries. Kidney Int 57(Suppl 74):S585–S593,early detection and treatment of renal disease at the
2000community level to prevent or slow progression of renal
21. Jha R, Kher V, Naik S: Hepatitis B associated liver disease in
failure, and education of the medical community and the dialysis patients: Role of vaccination. J Nephrol 6:98–102, 1994
22. Salunkhe PM, Naik SR, Kher V: Prevalence of antibodies topublic about organ donation and promoting cadaveric
hepatitis C virus in HBsAg negative hemodialysis patients. Indiantransplantation. Another important area is to increase
J Gastroenterol 11:164–165, 1992
the pool of trained nurses and nephrologists, which at 23. Huang CC: Hepatitis in patients with end stage renal disease. J
Gastroenterol Hepatol 12:S236–S241, 1997present is dismal.
24. Sakhuja V, Sud K, Maitra S: Prevalence of HIV infection in a
dialysis unit. Indian J Nephrol 4:42–44, 1994
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